Evidence map›Paper›PMID 37216624›Full record

ArticleJCO global oncology2023

Clinical Outcomes and Prognostic Factors of Patients With Early Malignant Melanoma in One Latin American Country: Results of the Epidemiological Registry of Malignant Melanoma in Colombia Study.

Aylen Vanessa Ospina Serrano, Fernando Contreras, Iván Triana, Guillermo Sánchez-Vanegas, Juan David Ortíz, Pedro Ramos, Claudia Vargas, Natalia Arango, Henry Idrobo, Isabel Munévar and 9 more

Open access · goldAbstract read
In one paragraph

Article in JCO global oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 11 institutions in 8 countries.

Aylen Vanessa Ospina SerranoAsociación Colombiana de Hematología y Oncología-ACHO, ICCAL Hospital, Universitario Fundación Santa Fe de Bogotá, Bogotá, Colombia.ORCID 0000-0002-4992-4306
Fernando ContrerasInstituto Nacional de Cancerología INC, Universidad El Bosque, Bogotá, Colombia.
Iván TrianaAsociación Colombiana de Hematología y Oncología-ACHO, ICCAL Hospital, Universitario Fundación Santa Fe de Bogotá, Bogotá, Colombia.
Guillermo Sánchez-VanegasHospital Universitario Mayor-Mederi, Universidad del Rosario, Bogotá, Colombia.
Juan David OrtízFundación Valle de Lili, Cali, Colombia.ORCID 0000-0001-5015-4380
Pedro RamosClínica Universitaria Colombia Sanitas, Oncocare, Bogotá, Colombia.
Claudia VargasCentro Oncológico Antioquia, Medellín, Colombia.
Natalia ArangoCentro Oncológico Antioquia, Medellín, Colombia.
Henry IdroboCentro Médico Julián Coronel, Universidad del Valle, Cali, Colombia.
Isabel MunévarHospital Militar Central, Fundación Cardio infantil, Hemato Oncólogos Asociados, Bogotá, Colombia.
Andrés YepesHospital Universitario San Vicente Fundación, Medellín, Colombia.
William MantillaFundación Cardio infantil, Universidad del Rosario, Grupo ICAROS, Bogotá, Colombia.
Paola JiménezHemato Oncólogos Asociados, Los Cobos Medical Center, Bogotá, Colombia.
Giovanna RivasClínica de Occidente, Cali, Colombia.
Mauricio LemaClínica de Oncología Astorga, Medellín, Colombia.
Carmen AlcaláClínica de la Costa, Barranquilla, Colombia.
Diego GómezFundación cardiovascular de Colombia, Hospital Internacional de Colombia, Bucaramanga, Colombia.
Matilde ChinchiaCosmitet, Clínica Rey David, Cali, Colombia.
Angela BarreroAsociación Colombiana de Hematología y Oncología-ACHO, Bogota, Colombia.
Roche (Switzerland) · CHAsociación Colombiana de Gastroenterología · COFundación Santa Fe de Bogotá · COClínica Santa María · COFundación Universitaria Sanitas · COHospital Militar Central · COUniversidad Autónoma de Occidente · COUniversidad del Rosario · COUniversidad del Valle · COUniversidad El Bosque · COUniversity of the Coast · CO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To describe the population with early malignant melanoma, we performed a cohort study on the basis of the Epidemiological Registry of Malignant Melanoma in Colombia-Asociacion Colombiana de Hematologia y Oncologia. From January 2011 until December 2021, 759 patients were included; the average age was 66 years, 57% were women, acral lentiginous histology was found in 27.8% of patients, and the median follow-up was 36.5 months. The prognostic factors for overall survival in our population are Eastern Cooperative Oncology Group 3-4 (hazard ratio [HR], 13.8), stage III (HR, 5.07), received radiotherapy (HR, 3.38), ulceration on histology (HR, 2.68), chronic sun exposure (HR, 2.3), low income (HR, 2.04), previous local surgery (HR, 0.27), and have received adjuvant treatment (HR, 0.41).

Indexed as

MelanomaAgedCohort StudiesColombiaCutaneous Malignant MelanomaFemaleHumansLatin AmericaMalePrognosisRegistries

Identifiers

PMID37216624
PMCPMC10497268
OpenAlexW4377293938

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.